Outcomes of Turkish National Breast Cancer Registry.
Bildiriler > Özet Bildiri
Yazarlar: Saadettin Kilickap, Mahmut Gumus, Dogan Uncu, Metin Ozkan, Irfan Cicin, Tamer E. Elkiran, Abdurrahman Isikdogan, Aziz Karaoglu, Berna Oksuzoglu, Feyyaz Ozdemir, Hande Turna, Ruchan Uslu, Ozgur Ozyilkan, Alper Erdogan, Burce Goktas, Oguz Kara
Journal of Clinical Oncology, , , Uluslararası, Özet Bildiri, Wos, cilt 35, ss e12517-e12517
DOI: 10.1200/jco.2017.35.15_suppl.e12517
Özet
Background: The aim of this registry was to collect demographic, diagnostic, treatment, and outcome information about Turkish patients with breast cancer (BC). Methods: It was designed as a multicenter, cross-sectional, non-interventional study conducted on new and previously diagnosed BC cases applied to 28 medical oncology outpatient clinics between 2012 and 2015. A total of 16841 male (n = 153) and female (n = 16688) patients > 18 years were included. Results: Mean age of BC patients was 52.0±11.5 years. Among women, 53.7% were postmenopausal, and 24.4% were receiving hormone replacement (HRT) and/or oral contraceptive therapies (OCT). At time of diagnosis, 18.2% of patients presented with Stage 1, 48.5% with Stage 2, 25.5% with Stage 3, and 7.9% with Stage 4 BC. In 79,8% of the patients histopathology was invasive ductal carcinoma. Estrogen (ER) and progesterone receptors (PR) were positive in 74.7%, and 69.4% of patients, respectively. Diagnostic immunohistochemistry (IHC) was performed in 90.4% of patients. HER2+ was found in 30.2% of patients. HER2+ was observed in 27.6% Stage I, 27.6% Stage II, 36.2% Stage III, and in 41.7% Stage 4 BC. ER and PR positivity were 62.4% and 56.4% among HER2+ patients, respectively. Neoadjuvant therapy was administered in 10.6% and adjuvant therapy was administered in 73.2% of patients. Between 2010 and 2015, trastuzumab was administered in 68.3% of adjuvant (n = 1959), and 7.5% of neoadjuvant (n = 215) HER2+ patients. Conclusions: BC is a major health concern. Majority of the patients are diagnosed in stage 2 or 3, therefore screening should be improved to diagnose patients at earlier stages. In HER2 positive patients, neoadjuvant trastuzumab usage is limited despite its known advantages.